All In Biotech

Drug Trial Radar · NCT05945537

A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH

A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Sep 8, 2023

Primary completion

May 31, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Inipharm Australia Pty LtdIndustry
Sponsor type
Industry
First posted
Jul 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 trial will explore the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of INI-822 in healthy volunteers in Parts A, B, D and F and in participants with a history of MASH or presumed MASH in Part C and in participants with MASH in E.

Conditions

  • Metabolic Dysfunction-Associated Steatohepatitis

Interventions

  • INI-822 (A)Drug

    Different dose levels of INI-822

  • Placebo (B)Other

    Matching placebo to INI-822

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs).Time frame: Part A: Up to 5 Weeks
  2. Incidence of adverse events (AEs).Time frame: Part A fasted fed crossover cohort: Up to 8 weeks
  3. Incidence of adverse events (AEs).Time frame: Part B: Up to 7 weeks
  4. Incidence of adverse events (AEs).Time frame: Part C: Up to 9 weeks
  5. Number of participants with clinical laboratory abnormalitiesTime frame: Part A: Up to 5 Weeks
  6. Number of participants with clinical laboratory abnormalitiesTime frame: Part A fasted fed crossover cohort: Up to 8 weeks
  7. Number of participants with clinical laboratory abnormalitiesTime frame: Part B: Up to 7 weeks
  8. Number of participants with clinical laboratory abnormalitiesTime frame: Part C: Up to 9 weeks
  9. Incidence of adverse events (AEs)Time frame: Part E: Up to 12 weeks
  10. Incidence of adverse events (AEs)Time frame: Part F: Up to 2 weeks
  11. Number of participants with clinical laboratory abnormalitiesTime frame: Part E: Up to 12Weeks
  12. Number of participants with clinical laboratory abnormalitiesTime frame: Part F: Up to 2Weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia · Recruiting

  • Campbelltown Hospital, Level 10, building A, Campbelltown Hospital, Therry Road,

    Campbelltown, New South Wales (nsw), Australia · Recruiting

  • Genesis Research Services, Ground Floor, 239/245 Denison Street Broadmeadow

    Newcastle, New South Wales (nsw), Australia · Recruiting

  • Ramsay Health North Shore, North Shore Private, 03 Westbourne Street

    Saint Leonards, New South Wales (nsw), Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • University of the Sunshine Coast Clinical Trials (Birtinya), UniSC Clinical Trials Vitality Village, Level 4, Tenancy 410, 5 Discovery Court

    Birtinya, Queensland (qld), Australia · Recruiting

  • Flinders Medical Centre, Flinders Medical Centre, Flinders

    Bedford Park, South Australia (SA), Australia · Recruiting

  • Box Hill Hospital, Level 1, 5 Arnold street

    Box Hill, Victoria, Australia · Recruiting

  • St. Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia · Recruiting

  • TrialsWest Pty Ltd, 90 Anstruther Road

    Mandurah, Western Australia (WA), Australia · Recruiting

  • TrialsWest Pty Ltd, 226 Main Street

    Osborne Park, Western Australia (WA), Australia · Recruiting

  • Westmead Hospital, Storr Liver Centre, Level 2, A/B Block, Westmead Hospital Corner Hawkesbury and Darcy Roads

    Westmead, Westmead, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.